BLND vs EHC: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BLND and EHC share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BLND and EHC exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Blend Labs is a cloud-based software company that powers digital-first consumer experiences for financial institutions in the United States and select international markets. Its platform lets banks, credit unions, and non-bank lenders originate and service a range of products through a single system, including mortgages, home equity loans and lines of credit, vehicle and personal loans, credit cards, and deposit accounts. Blend reports in two suites: the Mortgage Suite, historically its largest business, and the Consumer Banking Suite, which spans the broader deposit and non-mortgage lending products. The model is largely software subscription and usage revenue, supplemented by a smaller professional services line.

Full BLND guide

Encompass Health runs inpatient rehabilitation facilities, or IRFs: hospitals that take patients after a stroke, a hip fracture, a brain or spinal cord injury, or major surgery, and put them through intensive physician-supervised therapy before they go home. As of the second quarter of 2026 it operated 176 hospitals across 39 states and Puerto Rico, which makes it the largest operator in the category by a wide margin. Medicare fee-for-service is its dominant payer, and under the IRF prospective payment system it is paid a set amount per discharge based on the patient's condition and complexity, so revenue is essentially discharges multiplied by net revenue per discharge. A portion of its hospitals are structured as joint ventures with acute-care health systems, which brings referral flow and shared construction capital while handing a slice of consolidated profit to noncontrolling interests. The company became a pure-play rehabilitation operator in 2022 when it spun off its home health and hospice arm as Enhabit.

Full EHC guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BLND drivers: Mortgage Suite recovery; Consumer Banking diversification.
• EHC drivers: De novo hospitals and bed additions; Demographics against a supply-constrained niche.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is cyclicality: a large share of Blend's revenue is tied to mortgage origination, so a fresh downturn in housing or a jump in rates can quickly pressure its biggest suite. For EHC, encompass is heavily dependent on a single payer whose rates are set by regulation, so any policy shift toward site-neutral payment between rehabilitation hospitals and skilled nursing facilities would hit the core economics directly, and MedPAC has argued for years that IRF margins are high.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BLND if you believe its drivers more; EHC if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BLND and EHC guides.

BLND. Figures are approximate and tied to the asOf date; verify live numbers before acting. Blend is mid-turnaround, so headline revenue and margins can shift quarter to quarter, and non-GAAP operating income excludes items such as stock-based compensation that still affect GAAP results. Treat any valuation multiple as a bet on the profitability path rather than a reflection of steady current earnings, and check the latest filings for updated revenue, margin, and cash figures.

EHC. As of August 2026 the shares traded near $125, giving a market capitalization around $12.3 billion against trailing revenue of roughly $6.21 billion. Guided 2026 adjusted EPS of $6.02 to $6.25 puts the stock at about 20 times the midpoint, a premium to most hospital operators and a reflection of the visible bed pipeline rather than of any margin inflection. Second-quarter adjusted EBITDA margin was roughly 22 percent, and guidance was raised after the quarter rather than trimmed.

Headline figures (approximate, Jul 2026): BLND shows revenue trend Roughly $30 million in Q1 2026, back to modest year-over-year growth after a deep mortgage-driven downturn, gross margin Elevated for software, in the high-70s to around 80 percent on a non-GAAP basis, and expanding year over year, gaap profitability Still an operating loss, though the loss has narrowed materially, non-gaap operating income Modestly positive in recent quarters, a key part of the turnaround thesis; EHC shows revenue (ttm) ~$6.21B, q2 2026 revenue ~$1.60B, up ~9.6%, q2 2026 adjusted eps ~$1.55, fy2026 adjusted ebitda guidance ~$1.365B to $1.395B.

BLND and EHC are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BLND and EHC exposure against your real portfolio. It is not an investment adviser.